GenScript enhances cGMP Manufacturing Capacity for sgRNA and Non-Viral DNA Payloads capacity. The facility will be loacted in Jiangsu, China.
The new state-of-the-art facility provides gene therapy startups a quick way to access top-notch materials.
The recent expansion in Zhenjiang has introduced an additional 400,000 square feet of cGMP manufacturing space, creating room for growth and innovation.
As the field grows rapidly, there is an urgent need for non-viral GMP reagents. These materials help to move their new treatments from the early research stage to testing in people and eventually making them available for patients in less time than before.
This expansion includes the incorporation of four new production lines that are designed to cater to the growing demand for essential components in gene and cell therapies.
These cutting-edge production lines have the capability to efficiently produce significant amounts of sgRNA, ssDNA, or dsDNA per batch.
The primary focus is to maintain superior purity levels is crucial in ensuring the safety and effectiveness of the therapies being developed.